RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immix Biopharma Stock

Immix Biopharma Liabilities 2024

Immix Biopharma Liabilities

3.52 M USD

Ticker

IMMX

ISIN

US45258H1068

In 2024, Immix Biopharma's total liabilities amounted to 3.52 M USD, a 101.15% difference from the 1.75 M USD total liabilities in the previous year.

Immix Biopharma Aktienanalyse

What does Immix Biopharma do?

Immix Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Immix Biopharma's Liabilities

Immix Biopharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immix Biopharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Immix Biopharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Immix Biopharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Immix Biopharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Immix Biopharma stock

What is the level of liabilities of Immix Biopharma this year?

Immix Biopharma has a debt balance of 3.52 M USD this year.

What were the liabilities of Immix Biopharma compared to the previous year?

The liabilities of Immix Biopharma have increased by 101.15% increased compared to the previous year.

What are the consequences of high debt for investors of Immix Biopharma?

High liabilities can pose a risk for investors of Immix Biopharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Immix Biopharma?

Low liabilities mean that Immix Biopharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Immix Biopharma affect the company?

An increase in liabilities of Immix Biopharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Immix Biopharma affect the company?

A decrease in the liabilities of Immix Biopharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Immix Biopharma?

Some factors that can influence the liabilities of Immix Biopharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Immix Biopharma so important for investors?

The liabilities of Immix Biopharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Immix Biopharma take to modify the liabilities?

To change its liabilities, Immix Biopharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Immix Biopharma pay?

Over the past 12 months, Immix Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immix Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Immix Biopharma?

The current dividend yield of Immix Biopharma is .

When does Immix Biopharma pay dividends?

Immix Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immix Biopharma?

Immix Biopharma paid dividends every year for the past 0 years.

What is the dividend of Immix Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immix Biopharma located?

Immix Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immix Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immix Biopharma from 8/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Immix Biopharma pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Immix Biopharma in the year 2023?

In the year 2023, Immix Biopharma distributed 0 USD as dividends.

In which currency does Immix Biopharma pay out the dividend?

The dividends of Immix Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immix Biopharma

Our stock analysis for Immix Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immix Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.